A Study of ApricityRx™ for Management of IR-AEs in Patients on Immuno-Oncology Therapy

Apricity Health, Inc100 enrolled

Overview

Study of ApricityRx™ for Management of IR-AEs for patients on I-O therapy. Patients currently receiving immunotherapy will be asked to consent to participate in ApricityRx software platform mobile telephone application to report symptoms, view educational content in video form about IO and irAEs and communicate with site study team.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Cancer

Interventions

ApricityRx mobile applicationOTHER

AE detection and monitoring software

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Confirmed cancer diagnosis * Prescribed treatment with immune-checkpoint inhibitor * Age ≥ 18 years * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Uncomfortable with or unwilling to use digital or mobile technology * Lack of a smart phone with compatible operating systems: iOS version 10 and above, or Android 6.0 Marshmallow * Presence of any medical, psychological or social condition that, in the opinion of the investigator, would preclude participation in this study.

Locations (1)

Columbia University Irving Medical Center

New York, New York, United States

RECRUITING

Outcomes

Primary Outcomes

Evaluate digital therapeutic mobile app to capture and transmit to care team patient-generated health data and access education content on IO and irAEs

Number of times and percentage of study participants who use the app to report patient reported health data during a 12 week period and access education videos.

Time frame: 12 weeks

Central Contacts

Research Nurse Navigator

CONTACT

212-342-5162 cancerclinicaltrials@cumc.columbia.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.